Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCQ908 long-term open-label extension in familial chylomicronemia syndrome
NL-OMON41457Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pradigastat in primary chylomicronemia (FCS) (3 arms), sponsored by Novartis. Primary endpoint: Number of patients with adverse and serious adverse events. Started Oct 2013; status: active, not recruiting.
02
Drugs
pradigastat
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NL-OMON41457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41457.